Dr. Lal PathLabs has successfully completed its bonus share allotment, with the Board of Directors approving the issuance through a circular resolution on December 22, 2025. The company allotted 8,37,75,510 fully paid-up bonus equity shares in the ratio of 1:1 to eligible shareholders.

Bonus Share Allotment Details

The bonus shares were allotted to shareholders whose names appeared in the Register of Members or List of Beneficial Owners as of the record date of December 19, 2025. Each eligible shareholder received one new fully paid-up equity share for every existing share held.

Enhanced Capital Structure

Following the bonus share allotment, the company's paid-up equity share capital has doubled from ₹83.78 crores to ₹167.55 crores. The total number of outstanding shares increased from 8.38 crores to 16.76 crores.

Previous Corporate Actions

Prior to this allotment, the company had announced a second interim dividend of ₹7.00 per equity share for the financial year 2025-26, with a record date of November 7, 2025. The company had also paid an earlier interim dividend of ₹6.00 per share in August 2025.

The bonus shares allotted rank pari-passu in all respects with the existing fully paid-up equity shares of the company. The allotment was funded from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.

Dr. Lal Path Labs Limited has executed a Fifth Supplementary Trust Deed to amend its Employee Welfare Trust, incorporating the newly approved Restricted Stock Unit Plan 2025. The amendment was completed on December 9, 2025, and registered with the Sub-Registrar of Assurances in New Delhi on December 10, 2025.

New RSU Plan Integration

The trust deed amendment follows the shareholders' approval of the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025) through a special resolution passed on December 7, 2025. The modification ensures compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Trust Structure and Trustees

The Employee Welfare Trust operates under three designated trustees who will oversee the implementation of the new RSU plan:

• Mr. Munender Soperna: Group Chief Information & Digital Officer, aged 51 years
• Dr. Reena Nakra: Principal Director, Lab Management Technical Excellence, aged 53 years
• Mr. Manoj Kumar Garg: Group Chief Human Resources Officer, aged 57 years

Expanded Employee Benefit Plans

The amended trust deed now encompasses a comprehensive range of employee benefit schemes under the expanded definition of "Plan":

• Dr. Lal PathLabs Employee Stock Option Plan 2010 (ESOP 2010)
• Dr. Lal PathLabs Employee Share Purchase Scheme 2015 (ESPS 2015)
• Dr. Lal PathLabs Employee Restricted Stock Unit 2016 (RSU 2016)
• Dr. Lal PathLabs Employee Stock Option Plan 2022 (ESOP 2022)
• Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025)
• Any future employee benefit plans with provisions for modifications

Trust Evolution Timeline

The Employee Welfare Trust has undergone multiple amendments since its establishment:

Regulatory Compliance

The Fifth Supplementary Trust Deed maintains continuity with all previous amendments while specifically addressing the requirements of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The document establishes that in case of conflicts between different versions, the provisions of the Fifth Supplementary Trust Deed will prevail for matters specifically addressed therein.

The trust deed amendment represents Dr. Lal PathLabs' continued commitment to employee welfare through structured equity participation programs, ensuring regulatory compliance while expanding benefit options for eligible employees.